A SEQUENTIAL PHASE-II/III TRIAL FOR BINARY OUTCOMES

被引:18
作者
STORER, BE
机构
[1] Departments of Statistics and Human Oncology, University of Wisconsin, Medical Science Center, Madison, Wisconsin, 53706
关键词
D O I
10.1002/sim.4780090305
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This paper describes a simple two‐stage design for randomized clinical trials with a binary outcome. An early stopping criterion applies to results in the experimental arm only and seeks to evaluate that arm with respect to some external standard of efficacy. Stopping rules are similar to those commonly used in phase II designs. This design has no adverse impact on the overall type I error rate, though one must increase sample size to accommodate a modest loss in power. Copyright © 1990 John Wiley & Sons, Ltd.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 7 条
[1]  
Ellenberg S.S., Eisenberger M.A., An efficient design for Phase III studies of combination chemotherapies, Cancer Treatment Reports, 69, pp. 1147-1154, (1985)
[2]  
Wieand S., Therneau T., A two‐stage design for randomized trials with binary outcomes, Controlled Clinical Trials, 8, pp. 20-28, (1987)
[3]  
Bristol D.R., A one‐sided interim analysis with binary outcomes, Controlled Clinical Trials, 9, pp. 206-211, (1988)
[4]  
Thall P.F., Simon R., Ellenberg S.S., Shrager R., Optimal two‐stage designs for clinical trials with binary outcomes, Statistics in Medicine, 7, pp. 571-579, (1988)
[5]  
Fleming T.R., One‐sample multiple testing procedure for Phase II clinical trials, Biometrics, 38, pp. 143-151, (1982)
[6]  
Schaid D.J., Ingle J.N., Wieand S., Ahmann D.L., A design for Phase II testing of anticancer agents within a Phase III clinical trial, Controlled Clinical Trials, 9, pp. 107-118, (1988)
[7]  
Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S., Creech R.H., Mason B.A., Joss R.A., Vogl S., A randomized trial of the four most active regimens for metastatic non‐small‐cell lung cancer, Journal of Clinical Oncology, 4, pp. 14-22, (1986)